CareDx(CDNA) - 2024 Q1 - Earnings Call Presentation

7 Strong Testing Services Revenue Growth in Q1 2024 in millions USD Strong Year-Over-Year Revenue Growth Across Products and Digital Solutions Businesses Products Patient and Digital Solutions Significant Improvement in Adjusted EBITDA Losses in Q1 2024 1.Reported adjusted EBITDA losses; 2.Testing Services revenue associated with revenue cycle management (RCM) initiatives including collections from unpaid claims from test results delivered in prior quarters Revised 2024 Guidance | --- | --- | --- | --- | |- ...